Health and Healthcare

Bristol Myers Squibb : BMY

All Bristol Myers Squibb Articles

590 Articles

Chris Lange | Sep 7, 2017 at 12:10 PM EDT

How Bristol-Myers Actually Won by Stopping a Clinical Study

Usually when a clinical study is stopped it spells disaster for the company performing the study, but in this case…

Chris Lange | Aug 25, 2017 at 9:55 AM EDT

Short Sellers Run for Cover From Major Pharma

The August 15 short interest data have been compared with the previous figures, and short interest in most of these…

Chris Lange | Aug 10, 2017 at 8:40 AM EDT

Short Sellers Hike Bets in Major Pharma

The July 31 short interest data have been compared with the previous figures, and short interest in most of these…

Chris Lange | Jul 26, 2017 at 8:55 AM EDT

Major Pharma Short Interest Takes a Big Step Back

The July 14 short interest data have been compared with the previous figures, and short interest in most of these…

Chris Lange | Jul 21, 2017 at 8:37 AM EDT

Why Credit Suisse Prefers Johnson & Johnson Over Pfizer

Major pharmaceutical companies have posted a relatively positive year so far. Currently, Johnson & Johnson (NYSE: JNJ) is leading the…

Chris Lange | Jul 13, 2017 at 9:20 AM EDT

Major Pharma Short Sellers Become More Selective

The June 30 short interest data have been compared with the previous figures, and short interest moves in these selected…

Chris Lange | Jun 27, 2017 at 8:45 AM EDT

Short Sellers Run for Cover From Major Pharma

The June 15 short interest data have been compared with the previous figures, and short interest in most of these…

Jon C. Ogg | Jun 22, 2017 at 12:10 PM EDT

The Top 20 S&P 500 Companies Buying Back Stock in 2017

These are the top 20 stock buybacks in dollars spent during the first quarter of 2017 of all S&P 500…

Lee Jackson | Jun 12, 2017 at 10:10 AM EDT

4 Red-Hot Pharmaceutical and Biotechs Highlight Jefferies Top Stocks to Buy

A series of new reports from Jefferies focus on some of the top stocks in the pharmaceutical and biotech arenas.…

Chris Lange | Jun 12, 2017 at 8:55 AM EDT

Short Sellers Grow More Selective on Major Pharma

The May 31 short interest data have been compared with the previous figures, and short interest moves in these selected…

Chris Lange | Jun 6, 2017 at 1:25 PM EDT

Celldex Therapeutics Sinks Following ASCO Results

Celldex Therapeutics was another big mover coming out of the Annual Meeting for the American Society of Clinical Oncology (ASCO).…

Chris Lange | Jun 5, 2017 at 9:45 AM EDT

7 ASCO Stocks Moving on Cancer Study News (Updated)

The Annual Meeting for the American Society of Clinical Oncology (ASCO) is currently underway in Chicago, and the health care…

Chris Lange | Jun 2, 2017 at 1:35 PM EDT

15 Companies Bracing for Big ASCO Reactions

24/7 Wall St. takes a look at the ASCO annual meeting each year and picks out the companies that could…

Lee Jackson | May 25, 2017 at 10:15 AM EDT

Big Pharma Has Big Catalysts Coming for the Rest of 2017

A new Deutsche Bank research report focuses on the big capitalization pharmaceutical stocks and the upcoming catalysts and news flow…

Chris Lange | May 25, 2017 at 9:45 AM EDT

Major Pharma Short Interest Surges

The May 15 short interest data have been compared with the previous figures, and short interest moves in these selected…

1 … 18 19 20 21 22 … 40

Bristol Myers Squibb : BMY

All Bristol Myers Squibb Articles

How Bristol-Myers Actually Won by Stopping a Clinical Study

Short Sellers Run for Cover From Major Pharma

Short Sellers Hike Bets in Major Pharma

Major Pharma Short Interest Takes a Big Step Back

Why Credit Suisse Prefers Johnson & Johnson Over Pfizer

Major Pharma Short Sellers Become More Selective

Short Sellers Run for Cover From Major Pharma

The Top 20 S&P 500 Companies Buying Back Stock in 2017

4 Red-Hot Pharmaceutical and Biotechs Highlight Jefferies Top Stocks to Buy

Short Sellers Grow More Selective on Major Pharma

Celldex Therapeutics Sinks Following ASCO Results

7 ASCO Stocks Moving on Cancer Study News (Updated)

15 Companies Bracing for Big ASCO Reactions

Big Pharma Has Big Catalysts Coming for the Rest of 2017

Major Pharma Short Interest Surges

Here Are Tuesday’s Best Wall Street Analyst Research Calls: Centene, Darden Restaurants, Flutter Entertainment, GE Healthcare, IBM, Nike, SpaceX, Synopsys, Target, and More

3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal

Will the Tech Stock Rout Force Anthropic to Pull Its IPO?

5 Medicare Costs Went Up in 2026. The One That Stings Most Isn't Your Premium

Rule of 55: How Doctors With $1.6 Million 401(k)s Avoid the Penalty Trap

Here Are Tuesday’s Best Wall Street Analyst Research Calls: Centene, Darden Restaurants, Flutter Entertainment, GE Healthcare, IBM, Nike, SpaceX, Synopsys, Target, and More

3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal

Bristol Myers Squibb : BMY

All Bristol Myers Squibb Articles

How Bristol-Myers Actually Won by Stopping a Clinical Study

Short Sellers Run for Cover From Major Pharma

Short Sellers Hike Bets in Major Pharma

Major Pharma Short Interest Takes a Big Step Back

Why Credit Suisse Prefers Johnson & Johnson Over Pfizer

Major Pharma Short Sellers Become More Selective

Short Sellers Run for Cover From Major Pharma

The Top 20 S&P 500 Companies Buying Back Stock in 2017

4 Red-Hot Pharmaceutical and Biotechs Highlight Jefferies Top Stocks to Buy

Short Sellers Grow More Selective on Major Pharma

Celldex Therapeutics Sinks Following ASCO Results

7 ASCO Stocks Moving on Cancer Study News (Updated)

15 Companies Bracing for Big ASCO Reactions

Big Pharma Has Big Catalysts Coming for the Rest of 2017

Major Pharma Short Interest Surges

Here Are Tuesday’s Best Wall Street Analyst Research Calls: Centene, Darden Restaurants, Flutter Entertainment, GE Healthcare, IBM, Nike, SpaceX, Synopsys, Target, and More

3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal

Will the Tech Stock Rout Force Anthropic to Pull Its IPO?

Featured Reads

5 Medicare Costs Went Up in 2026. The One That Stings Most Isn't Your Premium

Rule of 55: How Doctors With $1.6 Million 401(k)s Avoid the Penalty Trap